Sarborg is a technology-driven company that integrates AI agents and mathematical algorithm- based approaches with complementary cybernetics to optimize decision-making processes. Its primary focus is on drug repurposing for pharmaceutical companies, leveraging machine learning and algorithmic strategies to enhance asset portfolio management and improve the probability of success in clinical trials.

The company is led by Dr. Andrew Regan, Chief Executive, who earned a PhD in 2014 for his research on bio-inspired algorithms in financial market forecasting. His thesis, A System to Predict the S&P 500 Using a Bio-Inspired Algorithm, demonstrated a 55.1% accuracy in forecasting next-day (t+1) directional trends of the S&P 500. Since its inception, Sarborg has applied its suite of AI agents, cybernetic algorithms and machine learning capabilities across various sectors, enabling a highly efficient decision-making process throughout its portfolio.

Traditional drug discovery, repurposing, and development timelines typically span 10 to 15 years from initial discovery to market approval. Sarborg disrupts this lengthy process by leveraging its advanced AI agents and cybernetics capabilities to identify high-potential drug assets, indications and combinations in less than six weeks, dramatically reducing the discovery phase.

Once an asset is identified through the Signature Agent, Sarborg utilizes its proprietary technology and multi-agent platform to repurpose it into the most suitable indications, optimizing its therapeutic potential. Following this, the company has the flexibility to either develop the product further or license it out to partners, supported by comprehensive data generated from its findings.

This innovative approach not only accelerates timelines but also maximizes efficiency and commercial potential, positioning Sarborg as a leader in next-generation pharmaceutical innovation.

Sarborg is strategically positioned to capitalize on the rapidly expanding market for drug repurposing and drug discovery, leveraging the increasing demand for innovative therapies and repurposed treatments through utilization of our combined AI agents, cybernetics and machine learning approach to drive growth in this evolving industry.

Sarborg’s Signature Agent uses proprietary AI to analyze drug and disease signatures, generating a compatibility score to identify high-potential repurposing, combination, and discovery opportunities across drug portfolios —enabling data-first decisions with unmatched speed.

High-level agent process diagram, further details are available upon execution of NDA

The illustration displays the multi-agent platform architecture, which constantly evaluates pharmaceutical assets to identify potential opportunities for Sarborg to take forward. These agents include:

Sarborg applies the Signature Agent to pharmaceutical client portfolios, offering fee-based or equity-linked analysis of repurposing potential, data room evaluation, and strategic development insights - including tailored recommendations to enhance IP position and unlock hidden value.

The image displays a dashboard developed for a Sarborg client. It includes information on patents that are nearing expiration, those that have been delisted, and those that have been recently approved or added to the database, aiming to provide pharmaceutical companies with a unique solution to identify and evaluate potential candidates for their future portfolio strategies.

The image showcases data related to patient subject information from clinical trials that are either ongoing or recently completed. The data is categorized by key patient demographics, including gender, race, age group, and disease or condition. It can be customized to align with a company’s specific focus or therapeutic area, enabling clients to identify the appropriate patient types for their clinical trials, streamline and enhance patient recruitment processes and gain deeper insights into how different patient groups may respond to a drug.

This strategy creates lasting value for partners and shareholders alike while advancing AI adoption across the industry.

Sarborg leverages proprietary AI agents and cybernetics to identify, develop, and partner pharmaceutical assets with unmatched speed, precision, and commercial upside.

Sarborg’s Proprietary Multi-Agent Platform

(currently under development) evaluates drug candidates across IP, market, and clinical dimensions using specific inputs.

/// Assets nearing patent expiry or with untapped clinical potential are transformed into differentiated, IP-protected products.

/// Solid-form engineering and novel formulation strategies unlock new, protectable value.

/// Enables market exclusivity, faster regulatory pathways, and strategic positioning for partnering..

From use of AI Agent to Asset Monetization

Once patented, Sarborg conducts targeted small animal studies to validate efficacy and de-risk development.

Preclinical data package supports partner licensing discussions, enabling pharma to:

/// Advance the asset into Phase II and beyond

/// Pay milestone payments and ongoing royalties

Once the product is protected, Sarborg has the flexibility to license it to the original innovator who has lost exclusivity or to competitors through a market-based pricing or bidding process. This strategy not only maximizes revenue potential but also strengthens Sarborg’s position as a leader in pharmaceutical innovation.